BresMed at Virtual ISPOR Europe 2021

30 November - 3 December 2021

This year’s theme for ISPOR is “Emerging Frontiers and Opportunities: Special Populations and Technologies.” While the conference is taking place virtually this year, we’re happy to still be contributing a range of workshops, panels and posters.

ISPOR normally provides us with the chance to catch up with the people we work with throughout the year, and though this year looks different we’re also still available to chat. You can contact us if you’d like to arrange a meeting or if you are attending the virtual event you can chat with us during the event by visiting our company page.

Workshops

Date & time Code Title Discussion leaders
Wednesday 1 December 12:30 – 13:30 206WK The Potential of R Shiny User Interfaces to Support Health Economic Decision Making Paul Schneider, Gianluca Baio, Rose Hart, Robert Smith.
Thursday 2 December
11:00 – 12:00
304WK Open Source Health Economics and Outcomes Research: Why and How to Do It? How to Connect with Users? Xavier Pouwels, Rose Hart, Stephanie Harvard, Howard Thom.
Friday 3 December
11:00 – 12:00
403WK SEE the Future: How Important Will Structured Expert Elicitation Become for HTA in the Next 5 Years? James Horscroft, Laura Bojke, Jeremy Edward Oakley.

Issue Panel

Date & time Code Title Moderator Panelists
Wednesday 1 December
16:00 – 17:00
 214IP  Is Regulatory Acceptance of Surrogate Endpoints for CAR-Ts a Sufficient Basis for Acceptance By HTA Bodies? Daniel Gladwell Oriana Ciani, Stephen Palmer, Adam Parnaby.

Posters

Session Code Title Authors
Clinical Outcomes: Oncology POSA25 An Incremental Effectiveness Analysis of Avelumab in Combination With Axitinib for the Treatment of First-Line Advanced Renal Cell Carcinoma in Portugal Silva Miguel L, Pinheiro B, Lopes R, Borges M, Kearney M, Zanotti G, Hart R, Smith S.
Clinical Outcomes: Oncology POSA33 Matching-adjusted Indirect Comparisons of Avapritinib Versus Midostaurin Among Patients with Advanced Systemic Mastocytosis Pilkington H, Smith S, Roskell N, Iannazzo S.
Health Policy & Regulatory: Oncology POSA221 5-Years On: Reflections on the Cancer Drugs Fund Critchlow S, Lilley C.
Clinical Outcomes: Cardiovascular Disorders POSB22 Indirect Treatment Comparisons of Empagliflozin versus Sacubitril + Valsartan for the Treatment of Patients with Heart Failure with Reduced Ejection Fraction Smith S, Pikington H, Roskell N, Linden S, Bellanca L.
Methodological & Statistical Research: Oncology POSB301 Development of a Sequencing Model Using Patient-level Data to Optimize Patient Outcomes in Multiple Myeloma Mendes J, Boer JH, Casamassima G, Willis A, Matthijsse S, Armeni P.
Real World Data & Information Systems: No Specific Disease POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making Sigurðardóttir K, Sola-Morales O, Murphy LA, Corry S, Mestre-Ferrandiz J, Cunningham D, Akehurst R, De Pouvourville G.
Economic Evaluation: Oncology POSC110 Cost-effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-year PACIFIC Data Mooradian MJ, Taylor S, Ramsden R, Keep M, Dunlop W, Brannman L, Yong C.
Methodological & Statistical Research: Biologics and Biosimilars POSC319 Analysis of Treatment Sequences across Seven Immunological Diseases and the Variability in Efficacy for Patients By Disease: Opportunities for Improvement Boer JH, Hassan F, Alulis-Nielsen S, Lee JM, Lee D.

We’d love to talk with you, contact us to arrange a meeting.

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies